In a nutshell This phase 2 clinical trial will test the effectiveness of poziotinib in treating locally advanced (spread to nearby tissue) or metastatic (spread to other parts of the body) non-small cell lung cancer (NSCLC) with an EGFR mutation. The primary outcome will be measured by the response rate to the treatment. This trial is being conducted...
Read MoreCurrent disease status-Recurrent cancer Posts on Medivizor
Early radiation therapy in men with recurrent prostate cancer after surgery
In a nutshell The authors aimed to determine patients who would benefit from early salvage radiation therapy (SRT) after prostate surgery. The authors concluded that early SRT is only beneficial for selected patients who experience cancer recurrence after prostate surgery. Some background Prostate surgery is a common prostate cancer...
Read MoreActivating the immune system to treat advanced non-small-cell lung cancer
In a nutshell This meta-analysis looks at the safety and effectiveness of a new type of treatment called immune checkpoint inhibitors (ICIs). The authors concluded that ICIs are safe and effective treatment for patients with advanced non-small-cell lung cancer (NSCLC). Some background The emergence of targeted therapy has been beneficial...
Read MoreAre multiple treatments better than one for treating advanced NSCLC?
In a nutshell This meta-analysis summarizes studies that looked at the effectiveness of erlotinib in combination with chemotherapy. This review is specific for patients with advanced NSCLC. The authors concluded that this combination is effective for NSCLC patients who have never smoked and who have EGFR mutations. Some background Lung cancer is...
Read MoreBrigatinib for the treatment of previously treated ALK-positive non-small-cell lung cancer
In a nutshell This trial examined a new therapy, brigatinib (Alunbrig), in treating patients with ALK-positive non-small-cell lung cancer (NSCLC) that has progressed passed initial treatments. The authors concluded that brigatinib was safe and effective at treating this type of cancer. Some background One type of NSCLC is caused by genetic...
Read MoreCan sentinel lymph node biopsy predict outcome in locally recurrent or in-transit melanomas?
In a nutshell This study investigated the role of sentinel node biopsy (SLNB) in locally recurrent (LR; when the cancer comes back) melanoma or in-transit (IT; spreads to a lymph vessel before it reaches the nearest lymph node) melanoma. Researchers suggested that SLNB should be performed in these patients. Some background The sentinel lymph node...
Read MoreOsimertinib is effective in pretreated non-small cell lung cancer with EGFR-T790M mutations
In a nutshell This trial examined the effectiveness and safety of osimertinib (Tagrisso) for treating patients with advanced non-small cell lung cancers that harbor T790M mutations. The authors concluded that the drug is promising in both safety and effectiveness at treating this type of cancer. Some background Non-small cell lung cancers...
Read MoreSearching for patients with previously treated stage 4 squamous cell lung cancer to test immunotherapies
In a nutshell This phase III trial aims to determine whether nivolumab (Opdivo) is effective at treating recurrent stage IV squamous cell lung cancer alone or in combination with ipilimumab (Yervoy). The main outcomes of the trial will be overall survival (time from beginning trial until death), progression free survival (time from beginning trial...
Read MoreHow effective is metronomic chemotherapy with vinorelbine and capecitabine in patients with advanced HER2-negative breast cancer?
In a nutshell This study investigated whether metronomic chemotherapy with oral vinorelbine (Navelbine) and capecitabine (Xeloda) was effective in treating patients with advanced HER2-negative breast cancer (BC). This form of treatment was found to be safe and effective for this patients group. Some background Metronomic chemotherapy is a form of...
Read MoreHow does hormone receptor status affect patient response to trastuzumab therapy in metastatic breast cancer
In a nutshell This study investigated the clinical factors that influence patient response to trastuzumab (Herceptin) therapy in human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer (MBC). Hormone receptor (HR) status was found to be a possible predictor of a strong response to trastuzumab-based therapy. Some background...
Read MoreComparing axillary lymph node ultrasound and fine needle aspiration in breast cancer
In a nutshell This study investigated whether patients with a suspicious axillary lymph node (ALN) but negative fine-needle aspiration result (FNA) can be considered as having node-negative disease (AUN). The study concluded that patients with suspicious ALN on ultrasound but negative FNA results can be treated as having node-negative disease. Some...
Read MoreCan radiation and hormone therapy after surgery improve prostate cancer survival rates?
In a nutshell The aim of this study was to determine whether radiation therapy in combination with hormonal therapy improved survival in men with prostate cancer that has spread to the lymph nodes after surgery. Researchers concluded that patients treated with radiation therapy and hormone therapy had a significantly higher survival rate compared to...
Read More
